The relationships between insulin and plasminogen activator inhibitor 1 levels: assessment in groups of subjects with dyslipidaemia and hypertension

Clinica Chimica Acta

Volumn 274, Issue 1, 1998, Pages 41-52

  Akanji, Abayomi O ^a,b   Al Shayji, Iqbal ^a,b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b MUBARAK AL KABEER HOSPITAL   (Kuwait)

Author keywords

Arabs; Coronary heart disease; Hyperlipidaemia; Insulin; Tissue plasminogen activator

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CORONARY DISEASE; FASTING; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN; KUWAIT; MALE; MIDDLE AGED; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS;

EID: 0032496661     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(98)00048-5     Document Type: Article

References (30)

1. [1] Ahmed AF, Abdelsalam SA, Mahmoud ME et al. A case control study of the incidence of coronary heart disease risk factors in Saudis at Almadina Almounawarah. Saudi Med J 1993;14:146-51.
2. [2] Radovanovic Z. Mortality patterns in Kuwait: inferences from death certificate data. Eur J Epidemiol 1994;10:733-6.
3. [3] Fraser D, Weitzman S, Blondheim S et al. The prevalence of cardiovascular risk factors among male Bedouins: a population in transition. Eur J Epidemiol 1990;6:273-8.
4. [4] El Mugamer IT, Ali Zayat AS, Hossain MM et al. Diabetes, obesity and hypertension in urban and rural people of Bedouin origin in the United Arab Emirates. J Trop Med Hyg 1995;98:407-15.
5. [5] Akanji AO, Al-Sulaiman A, Kinatamitath P et al. Profile of hyperlipidaemic patients in Kuwait: frequency of cardiovascular disease risk factors at presentation and initial response to treatment. J Kuwait Med Assoc 1997;29:25-33.
6. [6] Zavaroni I, Bonini L, Fantuzzi M et al. Hyperinsulinaemia, obesity and syndrome X. J Int Med 1994;235:51-6.
7. [7] Kaplan NM. The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridaemia and hypertension. Arch Intern Med 1989;149:1514-20.
8. [8] Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis. Bailliere's Clin Haematol 1995;8:345-63.
9. [9] Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
10. [10] Despres J-P, Lamarche B, Mauriege P et al. Hyperinsulinaemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
11. [11] Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457-62.
12. [12] Sundell IB, Nilsson TK, Ranby M et al. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein(a) and established cardiovascular risk factors in a North Swedish population. Atherosclerosis 1989;80:9-16.
13. [13] Akanji AO, Abdullah A, Tahzeeb S. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait. Eur J Clin Invest 1997;27:380-6.
14. [14] World Health Organization Expert Committee. Diabetes mellitus. Technical Report Series No. 727. Geneva:WHO, 1985.
15. [15] Akanji AO, Al-Suleiman AS, Tahzeeb S et al. A lipid clinic service in Kuwait: preliminary observations. Med Princ Pract 1996;5:151-9.
16. [16] World Health Organization Expert Committee. Arterial hypertension. Technical Report Series No. 628. Geneva: WHO, 1978.
17. [17] World Health Organisation. Measuring obesity: classification and distribution of anthropometric data. Copenhagen: WHO, 1989.
18. [18] Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative centrifuge. Clin Chem 1972;18:499-502.
19. [19] SPSS-X. User's Guide. 2nd Edition. New York: McGraw Hill, 1986.
20. [20] Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992;95:105-17.
21. [21] Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989;10:77-82.
22. [22] Hamsten A, Wiman B, DeFaire U et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
23. [23] Hamsten A, DeFaire U, Walldius G, Dahlen G, Szamosi A, Landou C et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;ii:3-9.
24. [24] Marques-Vidal P, Sie P, Cambou J-P et al. Relationships of plasminogen activator inhibitor and lipoprotein(a) with insulin, testosterone, 17b-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls. J Clin Endocrinol Metab 1995;80:1794-8.
25. [25] Gram J, Declerk PJ, Sidelman J. Multicentre evaluation of commercial kit methods: Plasminogen activator inhibitor activity. Thromb Haemost 1993;70:852-7.
26. [26] Saad MF, Lillioja S, Nyomba BL et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991;324:733-9.
27. [27] Joffe BI, Panz VR, Wing JR et al. Relationships between plasma insulin and blood pressure in South African black women in Johannesburg. Diabetes Care 1992;15:566-8.
28. [28] Yki-Jarvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995;38:1378-88.
29. [29] Juhan-Vague I, Roul C, Alessi MC et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemostasis 1989;6:370-3.
30. [30] Yudkin JS. Coronary heart disease in diabetes mellitus: three new risk factors and a unifying hypothesis. J Int Med 1995;238:21-30.